Eugia is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $5.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Eugia's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Oct 2020 | $2.7B |
| Jakafi | Incyte | Generic | 2028 | Settled, terms confidential | $3.1B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Eugia's share of it.